→ Prolific life-science developer Alexandria Real Estate Equities just plopped down $75M for a building in Long Island City fresh off the heels of its purchase of Pfizer HQ in Manhattan earlier this year.
→ Cambridge-based LogicBio is aiming for a $75 million haul during its IPO run. The gene editing company is looking to beef up its coffers for a Phase I/II run on methylmalonic acidemia (MMA). It will list under $LOGC on Nasdaq.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,300+ biopharma pros who read Endpoints News by email every day.Free Subscription